The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma

作者: Swaroop Revannasiddaiah , Subhash Chandra Joshi , Kailash Chandra Pandey , Madhup Rastogi , Mukesh Sharma

DOI: 10.3978/J.ISSN.2305-5839.2015.11.25

关键词:

摘要: Background: A considerable proportion of non-small cell lung carcinoma (NSCLC) patients are ineligible for radical therapies. Many frail not to tolerate intravenous palliative chemotherapy either. These often receive radiotherapy (RT), or supportive care alone. We intend compare outcomes with RT alone, versus plus oral low dose metronomic cyclophosphamide. Methods: Data was mined from 139 eligible NSCLC patient records. Comparisons were made between 65 treated January 2011 March 2013 (20-30 Gray in 5-10 fractions) 74 April December 2014 cyclophosphamide (50 mg once daily day initiation until at least the disease progression). Response assessed after 1-month post-RT by computed tomography. Patients complete partial response recorded as responders. For determination progression free survival (PFS), would be declared case increase size lesions, development new effusions. The proportions responders compared Fisher exact test, and PFS curves log-rank test. Results: Differences rates statistically insignificant. significantly higher when added comparison treatment alone (mean 3.1 vs . 2.55 months; P=0.0501). Further histological sub-group analysis revealed that enhanced addition limited adenocarcinoma histology (3.5 2.4 P=0.0053), while there no benefit those squamous (2.6 2.6 P=1). At used, instance any measurable hematological toxicity. Conclusions: pulmonary patients, is better than However, offered benefit. studies similar different agents justifiable.

参考文章(21)
Irappa Madabhavi, Swaroop Revannasiddaiah, Bhaskar Bhardwaj, Sridhar Papaiah Susheela, Priyanka Thakur, Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification Journal of Thoracic Disease. ,vol. 6, ,(2014) , 10.3978/J.ISSN.2072-1439.2014.05.19
Etsuyo Ogo, Hayato Kaida, Yuko Watanabe, Hidehiro Eto, Gen Suzuki, Chikayuki Hattori, Hiroaki Suefuji, Naofumi Hayabuchi, Chiyoko Tsuji, [Treatment with low-dose cyclophosphamide and radiation therapy for advanced non-small lung cancer in elderly patient]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 38, pp. 1503- ,(2011)
Adam J Olszewski, Shihab Ali, Sabrina M Witherby, None, Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. American Journal of Cancer Research. ,vol. 5, pp. 2229- 2240 ,(2015)
Romualdo Barroso-Sousa, Leonardo Gomes da Fonseca, Karla Teixeira Souza, Ana Carolina Ribeiro Chaves, Ariel Galapo Kann, Gilberto de Castro, Carlos Dzik, Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer Medical Oncology. ,vol. 32, pp. 443- ,(2015) , 10.1007/S12032-014-0443-4
Luis Paz-Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesús Corral, Symantha Melemed, William John, Nadia Chouaki, Annamaria H Zimmermann, Carla Visseren-Grul, Cesare Gridelli, None, Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncology. ,vol. 13, pp. 247- 255 ,(2012) , 10.1016/S1470-2045(12)70063-3
Y. Chen, O. Hyrien, P. Okunieff, K. Pandya, W. Wang, W. Liu, T. Smudzin, H. Choy, W. Curran, O-039 Impact of metronomic chemotherapy schedule on circulatingVEGF and bFGF during concurrent thoracic radiotherapy Lung Cancer. ,vol. 49, ,(2005) , 10.1016/S0169-5002(05)80171-0
David E Dawe, Peter Michael Ellis, None, The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach Frontiers in Oncology. ,vol. 4, pp. 178- 178 ,(2014) , 10.3389/FONC.2014.00178
Gianmauro Numico, Elvio Russi, Marco Merlano, Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer. ,vol. 32, pp. 213- 226 ,(2001) , 10.1016/S0169-5002(00)00222-1
Emilia Montagna, Giuseppe Cancello, Silvia Dellapasqua, Elisabetta Munzone, Marco Colleoni, Metronomic therapy and breast cancer: A systematic review Cancer Treatment Reviews. ,vol. 40, pp. 942- 950 ,(2014) , 10.1016/J.CTRV.2014.06.002
Yi-Bin Hao, Shan-Yong Yi, Jing Ruan, Ling Zhao, Ke-Jun Nan, New insights into metronomic chemotherapy-induced immunoregulation. Cancer Letters. ,vol. 354, pp. 220- 226 ,(2014) , 10.1016/J.CANLET.2014.08.028